Yue Leng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yue Leng has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Dayong Ren
College of Food Science and Engineering Jilin Agricultural University Changchun China
7 shared publications - Weihong Min
State Key Laboratory for Development and Utilization of Forest Food Resources, Zhejiang A&F University, Hangzhou 311300, China; Provincial Key Laboratory for Non-wood Forest and Quality Control and Utilization of Its Products, Zhejiang A&F University, Hangzhou 311300, China; College of Food and Health, Zhejiang A&F University, Hangzhou 311300, China
4 shared publications Xin Ma
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China
3 shared publicationsChunlei Liu
College of Food Science and Engineering, Jilin Agricultural University, Changchun 130118, P. R. China
2 shared publications- Chunlei Liu
College of Food Science and Engineering, Jilin Agricultural University, Changchun 130118, China
2 shared publications Dan Wu
College of Food Science and Engineering, Jilin Agricultural University, Changchun 130118, P. R. China
2 shared publications
Latest Publications
- 16 July 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- p. 1-17
Heat-Inactivated Lactiplantibacillus plantarum H6 Potentiates Low-Dose Simvastatin Efficacy Against Hypercholesterolemia in Mice Through Gut Microbiota Modulation
Due to the limited lipid-lowering effect of statins, combined lipid-lowering strategies have attracted much attention. This study aims to explore the improvement effect of the combined intake of postbiotics and low-dose simvastatin on hypercholesterolemic mice. In this study, mice with hypercholesterolemia model were established and administrated with low-dose simvastatin + inactivated Lactiplantibacillus plantarum H6 / surface layer protein / cell-bound exopolysaccharides for 8 weeks, it was found that the combined intake of iH6 and low-dose simvastatin could improve the blood lipid level of hypercholesterolemia mice, and the intake of iH6 did not affect the efficacy of simvastatin. The combined intake of iH6 and low-dose simvastatin significantly reduced the total TC levels in the serum, liver, ileum and feces of mice, as well as the serum LDL-C level compared with simvastatin alone. Moreover, it effectively improved liver injury, decreased the levels of serum ALT, AST and TBA, and alleviated liver oxidative stress, thereby protecting the liver. Further analysis of the intestinal microbiota and metabolites revealed that iH6 combined with low-dose simvastatin significantly increased the relative abundance of Alistipes, Enterorhabdus, Lachnospiraceae_NK4A136_group, norank_o__Clostridia_UCG-014 and Prevotellaceae_UCG-001 in the mouse gut, regulated the composition of the intestinal BA pool, especially secondary BAs, and maintained the dynamic balance of cholesterol levels in the body. In addition, compared with simvastatin alone, the combined effect of iH6 and low-dose simvastatin could increase the expression of transcriptional genes such as Ugt2b38, Cyp2e1, Cyp1a1, Cyp2c29, and Scd1 in the ileum, enhance the cholesterol metabolism-related pathways, and alleviate hypercholesterolemia in mice. In conclusion, this study evaluated the relationship between postbiotics (inactivated strains) and drug combination, aiming to reduce the use of drugs and promote the possibility of postbiotics as a drug companion, laying a foundation for the development and application of postbiotics in medical fields.
- 16 July 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- p. 1-17
Heat-Inactivated Lactiplantibacillus plantarum H6 Potentiates Low-Dose Simvastatin Efficacy Against Hypercholesterolemia in Mice Through Gut Microbiota Modulation
Due to the limited lipid-lowering effect of statins, combined lipid-lowering strategies have attracted much attention. This study aims to explore the improvement effect of the combined intake of postbiotics and low-dose simvastatin on hypercholesterolemic mice. In this study, mice with hypercholesterolemia model were established and administrated with low-dose simvastatin + inactivated Lactiplantibacillus plantarum H6 / surface layer protein / cell-bound exopolysaccharides for 8 weeks, it was found that the combined intake of iH6 and low-dose simvastatin could improve the blood lipid level of hypercholesterolemia mice, and the intake of iH6 did not affect the efficacy of simvastatin. The combined intake of iH6 and low-dose simvastatin significantly reduced the total TC levels in the serum, liver, ileum and feces of mice, as well as the serum LDL-C level compared with simvastatin alone. Moreover, it effectively improved liver injury, decreased the levels of serum ALT, AST and TBA, and alleviated liver oxidative stress, thereby protecting the liver. Further analysis of the intestinal microbiota and metabolites revealed that iH6 combined with low-dose simvastatin significantly increased the relative abundance of Alistipes, Enterorhabdus, Lachnospiraceae_NK4A136_group, norank_o__Clostridia_UCG-014 and Prevotellaceae_UCG-001 in the mouse gut, regulated the composition of the intestinal BA pool, especially secondary BAs, and maintained the dynamic balance of cholesterol levels in the body. In addition, compared with simvastatin alone, the combined effect of iH6 and low-dose simvastatin could increase the expression of transcriptional genes such as Ugt2b38, Cyp2e1, Cyp1a1, Cyp2c29, and Scd1 in the ileum, enhance the cholesterol metabolism-related pathways, and alleviate hypercholesterolemia in mice. In conclusion, this study evaluated the relationship between postbiotics (inactivated strains) and drug combination, aiming to reduce the use of drugs and promote the possibility of postbiotics as a drug companion, laying a foundation for the development and application of postbiotics in medical fields.
- Open Access
- 16 July 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 322, 120499
Ligilactobacillus salivarius-driven metabolic alterations of Staphylococcus aureus amplifies virulence and disrupts intestinal barrier homeostasis
- 16 July 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 322, 120499
Open AccessLigilactobacillus salivarius-driven metabolic alterations of Staphylococcus aureus amplifies virulence and disrupts intestinal barrier homeostasis
- Open Access
- 6 April 2026
- Published by Elsevier in Food Chemistry: X
- Vol. 35
Effect of thermosonication on quality and shelf-life of sweet cherry following cold storage
- 6 April 2026
- Published by Elsevier in Food Chemistry: X
- Vol. 35
Open AccessEffect of thermosonication on quality and shelf-life of sweet cherry following cold storage
- Open Access
Genome-Based Evaluation of Safety and Probiotic Traits in Infant Feces-Sourced Bifidobacterium animalis subsp. lactis BD1
Bifidobacterium animalis subsp. lactis is a widely used probiotic, yet its efficacy is highly strain-specific, and growing antibiotic resistance necessitates rigorous safety evaluations. We used whole-genome sequencing and in vitro assays to characterize the safety and probiotic traits of infant feces-sourced strain BD1, which shows preliminary mood-modulating and anti-inflammatory potential. The BD1 genome showed a favorable safety profile. VFDB analysis identified 139 low-similarity homologs, with no major toxins detected. Only four chromosomally encoded antibiotic resistance genes were found; phenotypic testing confirmed resistance solely to tetracycline and mupirocin. Although the tetracycline resistance gene tet(W) was identified in genomic island GI01, the absence of associated mobile genetic elements results in a negligible risk of its mobilization. Functional annotation highlighted a dominant metabolic capacity for carbohydrate and amino acid metabolism. BD1 is rich in CAZymes, enabling superior utilization of diverse substrates (starch, sucrose, galactose). Enrichment in lipid metabolism pathways (glycerolipid, sphingolipid) further suggests potential for enhancing fermented product flavor. In vitro assessment demonstrated moderate gastrointestinal tolerance and strong bile salt tolerance. Surface properties showed pronounced cell surface hydrophobicity and confirmed biofilm-forming potential. In conclusion, BD1 exhibits robust safety, metabolic versatility, and strong probiotic characteristics, supporting its development as a functional probiotic strain.
Open AccessGenome-Based Evaluation of Safety and Probiotic Traits in Infant Feces-Sourced Bifidobacterium animalis subsp. lactis BD1
Bifidobacterium animalis subsp. lactis is a widely used probiotic, yet its efficacy is highly strain-specific, and growing antibiotic resistance necessitates rigorous safety evaluations. We used whole-genome sequencing and in vitro assays to characterize the safety and probiotic traits of infant feces-sourced strain BD1, which shows preliminary mood-modulating and anti-inflammatory potential. The BD1 genome showed a favorable safety profile. VFDB analysis identified 139 low-similarity homologs, with no major toxins detected. Only four chromosomally encoded antibiotic resistance genes were found; phenotypic testing confirmed resistance solely to tetracycline and mupirocin. Although the tetracycline resistance gene tet(W) was identified in genomic island GI01, the absence of associated mobile genetic elements results in a negligible risk of its mobilization. Functional annotation highlighted a dominant metabolic capacity for carbohydrate and amino acid metabolism. BD1 is rich in CAZymes, enabling superior utilization of diverse substrates (starch, sucrose, galactose). Enrichment in lipid metabolism pathways (glycerolipid, sphingolipid) further suggests potential for enhancing fermented product flavor. In vitro assessment demonstrated moderate gastrointestinal tolerance and strong bile salt tolerance. Surface properties showed pronounced cell surface hydrophobicity and confirmed biofilm-forming potential. In conclusion, BD1 exhibits robust safety, metabolic versatility, and strong probiotic characteristics, supporting its development as a functional probiotic strain.
- 22 October 2025
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (3) , 4812-4829
Pasteurized Akkermansia muciniphila AKK PROBIO Attenuates Obesity Through Gut Microbiota-SCFA-GLP-1 Axis and Potential Involvement of AMPK/PPAR-α Pathway
Obesity pathogenesis is closely linked to gut microbiota dysbiosis. Akkermansia muciniphila (A. muciniphila) has emerged as a promising next-generation probiotic candidate due to its metabolic benefits. In this study, we systematically evaluated the therapeutic efficacy of pasteurized A. muciniphila AKK PROBIO (P-AKK PROBIO) in high-fat diet (HFD)-induced obese C57BL/6J mice. The results revealed that P-AKK PROBIO administration significantly ameliorated hepatic steatosis and reduced body weight and body fat percentage by 15.24% and 28.82% over four weeks, respectively. The intervention also improved serum lipid profiles by reducing total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), while increasing high-density lipoprotein cholesterol (HDL-C). Furthermore, P-AKK PROBIO attenuated TNF-α-mediated inflammatory responses. Mechanistically, P-AKK PROBIO enhanced intestinal barrier integrity through upregulation of tight junction proteins (ZO-1 and Occludin) and restored gut microbial homeostasis, as indicated by a decreased Firmicutes/Bacteroidetes ratio. Notably, the treatment enriched beneficial bacterial taxa (Oscillospiraceae and Roseburia) and increased short-chain fatty acids (SCFAs) production, particularly propionate, acetate, and butyrate. These microbial alterations correlated with elevated GLP-1 levels in both hypothalamic and ileal tissues, suggesting a dual mechanism involving GLP-1-dependent appetite regulation and lipid metabolism modulation. Furthermore, P-AKK PROBIO probably regulated key metabolic pathways by upregulating AMPK/PPAR-α signaling while downregulating PPAR-γ cascades. Collectively, these findings provide compelling evidence supporting the potential development of pasteurized A. muciniphila formulations for the management of metabolic disorders. Graphical Abstract
- 22 October 2025
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (3) , 4812-4829
Pasteurized Akkermansia muciniphila AKK PROBIO Attenuates Obesity Through Gut Microbiota-SCFA-GLP-1 Axis and Potential Involvement of AMPK/PPAR-α Pathway
Obesity pathogenesis is closely linked to gut microbiota dysbiosis. Akkermansia muciniphila (A. muciniphila) has emerged as a promising next-generation probiotic candidate due to its metabolic benefits. In this study, we systematically evaluated the therapeutic efficacy of pasteurized A. muciniphila AKK PROBIO (P-AKK PROBIO) in high-fat diet (HFD)-induced obese C57BL/6J mice. The results revealed that P-AKK PROBIO administration significantly ameliorated hepatic steatosis and reduced body weight and body fat percentage by 15.24% and 28.82% over four weeks, respectively. The intervention also improved serum lipid profiles by reducing total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), while increasing high-density lipoprotein cholesterol (HDL-C). Furthermore, P-AKK PROBIO attenuated TNF-α-mediated inflammatory responses. Mechanistically, P-AKK PROBIO enhanced intestinal barrier integrity through upregulation of tight junction proteins (ZO-1 and Occludin) and restored gut microbial homeostasis, as indicated by a decreased Firmicutes/Bacteroidetes ratio. Notably, the treatment enriched beneficial bacterial taxa (Oscillospiraceae and Roseburia) and increased short-chain fatty acids (SCFAs) production, particularly propionate, acetate, and butyrate. These microbial alterations correlated with elevated GLP-1 levels in both hypothalamic and ileal tissues, suggesting a dual mechanism involving GLP-1-dependent appetite regulation and lipid metabolism modulation. Furthermore, P-AKK PROBIO probably regulated key metabolic pathways by upregulating AMPK/PPAR-α signaling while downregulating PPAR-γ cascades. Collectively, these findings provide compelling evidence supporting the potential development of pasteurized A. muciniphila formulations for the management of metabolic disorders. Graphical Abstract
- Open Access
Correction: Fu et al. Synergistic Effect of Combined Walnut Peptide and Ginseng Extracts on Memory Improvement in C57BL/6 Mice and Potential Mechanism Exploration. Foods 2023, 12, 2329
The authors would like to make the following correction to a published paper
Open AccessCorrection: Fu et al. Synergistic Effect of Combined Walnut Peptide and Ginseng Extracts on Memory Improvement in C57BL/6 Mice and Potential Mechanism Exploration. Foods 2023, 12, 2329
The authors would like to make the following correction to a published paper
- Open Access
Uncovering the Beneficial Role of Limosilactobacillus fermentum E7 Exhibiting Antioxidant Activity in Ameliorating DSS-Induced Ulcerative Colitis in a Murine Model
Background: Ulcerative colitis (UC) is a chronic intestinal disease of growing global concern. Bacteria associated with fermented food or probiotics regulate immune and inflammatory responses, playing a key role in intestinal immune homeostasis. Results: Five probiotics with relatively good antioxidant effects, namely Lactiplantibacillus plantarum H6, Latilactobacillus sakei QC9, Limosilactobacillus fermentum E7, Bacillus subtills D1, and Bacillus licheniformis Q13, were screened out from 30 strains of probiotics through in vitro antioxidant assays. The five probiotics had varying degrees of alleviating effects on UC mice and improved various physiological indicators, such as oxidative stress parameters and histopathological sections. The effects of E7, D1, and Q13 were more pronounced. Furthermore, E7 effectively regulated UC mouse intestinal microbiota composition, increased short-chain fatty acid concentration, and promoted the expression of anti-inflammatory factors, such as interleukin 10 (IL-10), while suppressing that of pro-inflammatory factors, such as interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α). Meanwhile, D1 and Q13 only exhibited partial alleviating effects. Finally, E7 increased the expression of tight junction proteins in colon tissues. Conclusions: E7 showed superior efficacy to other probiotics in alleviating UC, offering novel therapeutic prospects for safer and effective management of UC.
Open AccessUncovering the Beneficial Role of Limosilactobacillus fermentum E7 Exhibiting Antioxidant Activity in Ameliorating DSS-Induced Ulcerative Colitis in a Murine Model
Background: Ulcerative colitis (UC) is a chronic intestinal disease of growing global concern. Bacteria associated with fermented food or probiotics regulate immune and inflammatory responses, playing a key role in intestinal immune homeostasis. Results: Five probiotics with relatively good antioxidant effects, namely Lactiplantibacillus plantarum H6, Latilactobacillus sakei QC9, Limosilactobacillus fermentum E7, Bacillus subtills D1, and Bacillus licheniformis Q13, were screened out from 30 strains of probiotics through in vitro antioxidant assays. The five probiotics had varying degrees of alleviating effects on UC mice and improved various physiological indicators, such as oxidative stress parameters and histopathological sections. The effects of E7, D1, and Q13 were more pronounced. Furthermore, E7 effectively regulated UC mouse intestinal microbiota composition, increased short-chain fatty acid concentration, and promoted the expression of anti-inflammatory factors, such as interleukin 10 (IL-10), while suppressing that of pro-inflammatory factors, such as interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α). Meanwhile, D1 and Q13 only exhibited partial alleviating effects. Finally, E7 increased the expression of tight junction proteins in colon tissues. Conclusions: E7 showed superior efficacy to other probiotics in alleviating UC, offering novel therapeutic prospects for safer and effective management of UC.
- Open Access
- 22 April 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (9) , 5176-5177
Correction: Therapeutic effects of a walnut-derived peptide on NLRP3 inflammasome activation, synaptic plasticity, and cognitive dysfunction in T2DM mice
Correction for ‘Therapeutic effects of a walnut-derived peptide on NLRP3 inflammasome activation, synaptic plasticity, and cognitive dysfunction in T2DM mice’ by Yanru Li et al., Food Funct., 2024, 15, 2295–2313, https://doi.org/10.1039/D3FO05076A.
- 22 April 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (9) , 5176-5177
Open AccessCorrection: Therapeutic effects of a walnut-derived peptide on NLRP3 inflammasome activation, synaptic plasticity, and cognitive dysfunction in T2DM mice
Correction for ‘Therapeutic effects of a walnut-derived peptide on NLRP3 inflammasome activation, synaptic plasticity, and cognitive dysfunction in T2DM mice’ by Yanru Li et al., Food Funct., 2024, 15, 2295–2313, https://doi.org/10.1039/D3FO05076A.
- 31 January 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (4) , 2295-2313
Therapeutic effects of a walnut-derived peptide on NLRP3 inflammasome activation, synaptic plasticity, and cognitive dysfunction in T2DM mice
NLRP3 inflammasome activation plays a key role in the development of diabetes-induced cognitive impairment.
- 31 January 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (4) , 2295-2313
Therapeutic effects of a walnut-derived peptide on NLRP3 inflammasome activation, synaptic plasticity, and cognitive dysfunction in T2DM mice
NLRP3 inflammasome activation plays a key role in the development of diabetes-induced cognitive impairment.